[HTML][HTML] Statins: a repurposed drug to fight cancer

W Jiang, JW Hu, XR He, WL Jin, XY He - Journal of Experimental & …, 2021 - Springer
As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol
and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of …

Large and small animal models of heart failure with reduced ejection fraction

PM Pilz, JE Ward, WT Chang, A Kiss, E Bateh… - Circulation …, 2022 - Am Heart Assoc
Heart failure (HF) describes a heterogenous complex spectrum of pathological conditions
that results in structural and functional remodeling leading to subsequent impairment of …

[HTML][HTML] Cardiac remodeling in heart failure: role of pyroptosis and its therapeutic implications

R Chai, W Xue, S Shi, Y Zhou, Y Du, Y Li… - Frontiers in …, 2022 - frontiersin.org
Pyroptosis is a kind of programmed cell death closely related to inflammation. The pathways
that mediate pyroptosis can be divided into the Caspase-1-dependent canonical pathway …

[HTML][HTML] Unraveling the anticancer potential of statins: Mechanisms and clinical significance

MY Zaky, C Fan, H Zhang, XF Sun - Cancers, 2023 - mdpi.com
Simple Summary Statins are crucial for managing lipid disorders by inhibiting HMG-CoA
reductase, reducing cholesterol levels, and lowering cardiovascular disease risk. Beyond …

[HTML][HTML] Targeting the tumor microenvironment: a literature review of the novel anti-tumor mechanism of statins

PF Zhu, MX Wang, ZL Chen, L Yang - Frontiers in oncology, 2021 - frontiersin.org
Statins is widely used in clinical practice as lipid-lowering drugs and has been proven to be
effective in the treatment of cardiovascular, endocrine, metabolic syndrome and other …

[HTML][HTML] Novel insights and current evidence for mechanisms of atherosclerosis: mitochondrial dynamics as a potential therapeutic target

D Li, S Yang, Y Xing, L Pan, R Zhao, Y Zhao… - Frontiers in Cell and …, 2021 - frontiersin.org
Cardiovascular disease (CVD) is the main cause of death worldwide. Atherosclerosis is the
underlying pathological basis of CVD. Mitochondrial homeostasis is maintained through the …

[HTML][HTML] Statins as anti-pyroptotic agents

M Khalifeh, PE Penson, M Banach… - Archives of Medical …, 2021 - ncbi.nlm.nih.gov
Methods Appropriate inflammatory responses and the induction of pyroptosis enhance the
clearance of pathogens and increase innate immunity. Results However, excessive …

[HTML][HTML] NLRP3-mediated pyroptosis in diabetic nephropathy

J Wan, D Liu, S Pan, S Zhou, Z Liu - Frontiers in pharmacology, 2022 - frontiersin.org
Diabetic nephropathy (DN) is the main cause of end-stage renal disease (ESRD), which is
characterized by a series of abnormal changes such as glomerulosclerosis, podocyte loss …

[HTML][HTML] Gasdermin D-mediated pyroptosis in myocardial ischemia and reperfusion injury: Cumulative evidence for future cardioprotective strategies

P Yanpiset, C Maneechote, S Sriwichaiin… - … Pharmaceutica Sinica B, 2023 - Elsevier
Cardiomyocyte death is one of the major mechanisms contributing to the development of
myocardial infarction (MI) and myocardial ischemia/reperfusion (MI/R) injury. Due to the …

[HTML][HTML] Regulation of pyroptosis in cardiovascular pathologies: Role of noncoding RNAs

J Gao, X Chen, P Wei, Y Wang, P Li, K Shao - Molecular Therapy-Nucleic …, 2021 - cell.com
Cardiovascular disease (CVD) is one of the most important diseases endangering human
life. The pathogenesis of CVDs is complex. Pyroptosis, which differs from traditional …